Search Results - "Oaks, Joshua J"

Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation by Panneer Selvam, Shanmugam, De Palma, Ryan M, Oaks, Joshua J, Oleinik, Natalia, Peterson, Yuri K, Stahelin, Robert V, Skordalakes, Emmanuel, Ponnusamy, Suriyan, Garrett-Mayer, Elizabeth, Smith, Charles D, Ogretmen, Besim

“…During DNA replication, the enzyme telomerase maintains the ends of chromosomes, called telomeres. Shortened telomeres trigger cell senescence, and cancer…”
Get more information

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells by Neviani, Paolo, Harb, Jason G, Oaks, Joshua J, Santhanam, Ramasamy, Walker, Christopher J, Ellis, Justin J, Ferenchak, Gregory, Dorrance, Adrienne M, Paisie, Carolyn A, Eiring, Anna M, Ma, Yihui, Mao, Hsiaoyin C, Zhang, Bin, Wunderlich, Mark, May, Philippa C, Sun, Chaode, Saddoughi, Sahar A, Bielawski, Jacek, Blum, William, Klisovic, Rebecca B, Solt, Janelle A, Byrd, John C, Volinia, Stefano, Cortes, Jorge, Huettner, Claudia S, Koschmieder, Steffen, Holyoake, Tessa L, Devine, Steven, Caligiuri, Michael A, Croce, Carlo M, Garzon, Ramiro, Ogretmen, Besim, Arlinghaus, Ralph B, Chen, Ching-Shih, Bittman, Robert, Hokland, Peter, Roy, Denis-Claude, Milojkovic, Dragana, Apperley, Jane, Goldman, John M, Reid, Alistair, Mulloy, James C, Bhatia, Ravi, Marcucci, Guido, Perrotti, Danilo

“…The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends on the requirement for BCR-ABL1 kinase activity in CML…”
Get full text

miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts by Eiring, Anna M., Harb, Jason G., Neviani, Paolo, Garton, Christopher, Oaks, Joshua J., Spizzo, Riccardo, Liu, Shujun, Schwind, Sebastian, Santhanam, Ramasamy, Hickey, Christopher J., Becker, Heiko, Chandler, Jason C., Andino, Raul, Cortes, Jorge, Hokland, Peter, Huettner, Claudia S., Bhatia, Ravi, Roy, Denis C., Liebhaber, Stephen A., Caligiuri, Michael A., Marcucci, Guido, Garzon, Ramiro, Croce, Carlo M., Calin, George A., Perrotti, Danilo

“…MicroRNAs and heterogeneous ribonucleoproteins (hnRNPs) are posttranscriptional gene regulators that bind mRNA in a sequence-specific manner. Here, we report…”
Get full text

The NMR‐based characterization of the FTY720‐SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET‐PP2A interaction by De Palma, Ryan M., Parnham, Stuart R., Li, Yitong, Oaks, Joshua J., Peterson, Yuri K., Szulc, Zdzislaw M., Roth, Braden M., Xing, Yongna, Ogretmen, Besim

“…ABSTRACT The su(var)3‐9, enhancer of zeste, trithorax (SET)/inhibitor 2 of protein phosphatase 2A (PP2A) oncoprotein binds and inhibits PP2A, composed of…”
Get full text

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias by Walker, Christopher J., Oaks, Joshua J., Santhanam, Ramasamy, Neviani, Paolo, Harb, Jason G., Ferenchak, Gregory, Ellis, Justin J., Landesman, Yosef, Eisfeld, Ann-Kathrin, Gabrail, Nash Y., Smith, Carrie L., Caligiuri, Michael A., Hokland, Peter, Roy, Denis Claude, Reid, Alistair, Milojkovic, Dragana, Goldman, John M., Apperley, Jane, Garzon, Ramiro, Marcucci, Guido, Shacham, Sharon, Kauffman, Michael G., Perrotti, Danilo

“…As tyrosine kinase inhibitors (TKIs) fail to induce long-term response in blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia…”
Get full text

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies by Oaks, Joshua J., Santhanam, Ramasamy, Walker, Christopher J., Roof, Steve, Harb, Jason G., Ferenchak, Greg, Eisfeld, Ann-Kathrin, Van Brocklyn, James R., Briesewitz, Roger, Saddoughi, Sahar A., Nagata, Kyosuke, Bittman, Robert, Caligiuri, Michael A., Abdel-Wahab, Omar, Levine, Ross, Arlinghaus, Ralph B., Quintas-Cardama, Alfonso, Goldman, John M., Apperley, Jane, Reid, Alistair, Milojkovic, Dragana, Ziolo, Mark T., Marcucci, Guido, Ogretmen, Besim, Neviani, Paolo, Perrotti, Danilo

“…FTY720 (Fingolimod, Gilenya) is a sphingosine analog used as an immunosuppressant in multiple sclerosis patients. FTY720 is also a potent protein phosphatase…”
Get full text

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia by Neviani, Paolo, Santhanam, Ramasamy, Oaks, Joshua J, Eiring, Anna M, Notari, Mario, Blaser, Bradley W, Liu, Shujun, Trotta, Rossana, Muthusamy, Natarajan, Gambacorti-Passerini, Carlo, Druker, Brian J, Cortes, Jorge, Marcucci, Guido, Chen, Ching-Shih, Verrills, Nicole M, Roy, Denis C, Caligiuri, Michael A, Bloomfield, Clara D, Byrd, John C, Perrotti, Danilo

“…Blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia chromosome-positive (Ph1-positive) acute lymphocytic leukemia (ALL) are 2 fatal…”
Get full text

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia by Alachkar, Houda, Santhanam, Ramasamy, Harb, Jason G, Lucas, David M, Oaks, Joshua J, Hickey, Christopher J, Pan, Li, Kinghorn, A Douglas, Caligiuri, Michael A, Perrotti, Danilo, Byrd, John C, Garzon, Ramiro, Grever, Michael R, Marcucci, Guido

“…Activating mutations [internal tandem duplication (ITD)] or overexpression of the FMS-like tyrosine kinase receptor-3 (FLT3) gene are associated with poor…”
Get full text

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis by Eiring, Anna M., Neviani, Paolo, Santhanam, Ramasamy, Oaks, Joshua J., Chang, Ji Suk, Notari, Mario, Willis, William, Gambacorti-Passerini, Carlo, Volinia, Stefano, Marcucci, Guido, Caligiuri, Michael A., Leone, Gustavo W., Perrotti, Danilo

“…Several RNA binding proteins (RBPs) have been implicated in the progression of chronic myelogenous leukemia (CML) from the indolent chronic phase to the…”
Get full text

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL by Walker, Christopher J, Oaks, Joshua J, Santhanam, Ramasamy, Neviani, Paolo, Harb, Jason G, Ferenchak, Gregory, Ellis, Justin, Marcucci, Guido, Landesman, Yosef, Shacham, Sharon, Kauffman, Michael, Perrotti, Danilo

“…Abstract 35 As tyrosine kinase inhibitors (TKIs) do not induce long-term response in blast crisis chronic myeloid leukemia (CML-BC) or Philadelphia…”
Get full text

Abstract 3839: Nuclear export (karyopherin) inhibitors: A novel therapeutic strategy for treating Philadelphia-positive (Ph+) acute leukemias by Walker, Christopher, Oaks, Joshua J., Santhanam, Ramasamy, Neviani, Paolo, Harb, Jason G., Paisie, Carolyn, Marcucci, Guido, Landesman, Yosef, Shacham, Sharon, Kauffman, Michael, Perrotti, Danilo

“…Tyrosine kinase inhibitor (TKI)-based therapies do not induce long-term response in myeloid or lymphoid blast crisis (BC) chronic myelogenous leukemia (CML)…”
Get full text

Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity by Walker, Christopher J, Oaks, Joshua J, Santhanam, Ramasamy, Neviani, Paolo, Harb, Jason G, Paisie, Carolyn, Marcucci, Guido, Shacham, Sharon, Kauffman, Michael, Perrotti, Danilo

“…Abstract 3758 Despite the remarkable response in chronic phase CML, tyrosine kinase inhibitor (TKI)-based therapies do not induce long-term response in myeloid…”
Get full text

The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML by Harb, Jason G, Neviani, Paolo, Oaks, Joshua J, Marcucci, Guido, Hokland, Peter, Roy, Denis-Claude, Perrotti, Danilo

“…Abstract 1222 The molecular mechanism leading to disease progression of chronic myelogenous leukemia (CML) still remains to be identified although enhanced…”
Get full text

Activating PP2A Tumor Suppressor Activity as a Potential Therapy for Treating Jak2 V617F-Driven Myeloproliferative Disorders by Oaks, Joshua J., Santhanam, Ramasamy, Briesewitz, Roger, Perrotti, Danilo

“…Polycythemia vera (PV) is a myeloproliferative disorder (MPD) caused by a valine to phenylalanine mutation in the inhibitory JH2 “pseudokinase” domain of the…”
Get full text

FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34+ Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration by Oaks, Joshua J, Mukhopadhyay, A., Santhanam, Ramasamy, Saddoughi, S. A, Neviani, Paolo, Harb, Jason G, Ogretmen, Besim, Bittman, Robert, Levine, Ross L, Quintás-Cardama, Alfonso, Marcucci, Guido, Perrotti, Danilo

“…Abstract 2494 In CD34+ bone marrow (BM) progenitors from Polycythemia Vera (PV) patients and Jak2V617F-expressing cell lines, loss of protein phosphatase 2A…”
Get full text

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives by Walker, Christopher, Oaks, Joshua J, Neviani, Paolo, Harb, Jason G, Santhanam, Ramasamy, Ma, Y., Marcucci, Guido, Van Brocklyn, James, Chen, Ching-Shih, Bittman, Robert, Perrotti, Danilo

“…Abstract 2901 FTY720 is a sphingosine analog proposed by the FDA for treating Multiple Sclerosis patients because of its immunosuppressive activity, which…”
Get full text

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders by Oaks, Joshua J, Mukhopadhyay, A., Santhanam, Ramasamy, Saddoughi, S. A, Walker, Christopher, Neviani, Paolo, Harb, Jason G, Ma, Y., Verstovsek, Srdan, Marcucci, Guido, Briesewitz, Roger, Bittman, Robert, Chen, Ching-Shih, Quintas-Cardama, Alfonso, Ogretmen, Besim, Perrotti, Danilo

“…Abstract 775 We have shown (Oaks JJ et al. ASH 2009) that the tumor suppressor Protein Phosphatase 2A (PP2A) is functionally inactivated by Jak2V617F in cell…”
Get full text

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment by Neviani, Paolo, Harb, Jason G, Oaks, Joshua J, Walker, Christopher, Santhanam, Ramasamy, Paisie, Carolyn, Eiring, Anna, Zhang, Bin, Perazzona, Bastianella, Ma, Y., Mao, Charlene, Marcucci, Guido, Holyoake, Tessa L., Volinia, Stefano, Cortes, Jorge E., Caligiuri, Michael A., Huettner, Claudia, Bittman, Robert, Chen, Ching-Shih, Arlinghaus, Ralph B., Hokland, Peter, Roy, Denis-Claude, Bhatia, Ravi, Perrotti, Danilo

“…Abstract 515 The success of tyrosine kinase inhibitors as first line therapy for t(9;22) Chronic Myelogenous Leukemia (CML) depends on the addiction that…”
Get full text

Abstract 1950: Suppression of RISC-independent decoy and RISC-mediated RNA-pairing activities of microRNA-328 is required for maturation-arrest and enhanced survival of blast crisis CML progenitors by Eiring, Anna M., Harb, Jason, Neviani, Paolo, Oaks, Joshua J., Liu, Shujun, Spizzo, Riccardo, Schwind, Sebastian, Santhanam, Ramasamy, Hickey, Christopher, Becker, Heiko, Chandler, Jason C., Andino, Raul, Cortes, Jorge, Hokland, Peter, Huettner, Claudia S., Bhatia, Ravi, Roy, Denis C., Liebhaber, Stephen, Caligiuri, Michael A., Marcucci, Guido, Garzon, Ramiro, Croce, Carlo M., Calin, George A., Perrotti, Danilo

“…MicroRNAs (miRs) and heterogeneous ribonucleoproteins (hnRNPs) are post-transcriptional gene regulators that bind to mRNA in a sequence-specific manner. We…”
Get full text

Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis by Eiring, Anna M., Neviani, Paolo, Santhanam, Ramasamy, Oaks, Joshua J., Chang, Ji Suk, Gambacorti-Passerini, Carlo, Volinia, Stefano, Marcucci, Guido, Caligiuri, Michael A., Leone, Gustavo W., Perrotti, Danilo

“…Several RNA binding proteins (RBPs) have been implicated in the progression of chronic myelogenous leukemia (CML) from the indolent chronic phase to the…”
Get full text